Table 1 Baseline characteristics of the total participants
| Â | Cancer-related stroke | Control | p value |
|---|---|---|---|
n (%) or mean ± SD or median (IQR) | n (%) or mean ± SD or median (IQR) | ||
Total | 34 (100%) | 307 (100%) | Â |
Age, years | 64.5 ± 11.4 | 68.9 ± 14.0 | 0.124 |
Sex, male [n (%)] | 17 (50%) | 161 (52.4%) | 0.921 |
Premorbid mRS score | 0 (0–1.75) | 0 (0–0) | 0.294 |
Baseline NIHSS score | 18 (11–23) | 15 (8–19) | 0.290 |
Comorbidities | |||
 Hypertension | 22 (64.7%) | 219 (71.3%) | 0.768 |
 Diabetes | 14 (41.1%) | 106 (34.5%) | 0.621 |
 Hyperlipidemia | 9 (26.5%) | 139 (45.3%) | 0.328 |
 Coronary artery disease | 5 (14.7%) | 59 (19.2%) | 0.142 |
 Prior stroke or TIA | 6 (17.7%) | 82 (26.7%) | 0.306 |
 Smoking | 5 (14.7%) | 92 (30.0%) | 0.072 |
 Atrial fibrillation | 0 (0%) | 175 (57.0%) | < 0.001 |
Previous use of antithrombotics†| 13 (38.2%) | 98 (31.9%) | 0.336 |
Laboratory findings | |||
 Hemoglobin, g/dℓ | 10.8 ± 2.1 | 13.1 ± 2.1 | < 0.001 |
 White blood cells, 103/μL | 10.7 ± 6.3 | 8.8 ± 3.5 | 0.042 |
 Platelet counts, 103/μL | 187.7 ± 105.9 | 216.3 ± 72.3 | < 0.001 |
 Prothrombin time, sec/INR | 1.2 ± 0.2 | 1.1 ± 0.3 | 0.562 |
 Total cholesterol, mg/dℓ | 150.2 ± 47 | 160.2 ± 42.3 | 0.134 |
 Triglyceride, mg/dℓ | 110.4 ± 52.7 | 99.0 ± 53.5 | 0.172 |
 HDL cholesterol, mg/dℓ | 38.1 ± 17 | 47.2 ± 15.1 | 0.094 |
 LDL cholesterol, mg/dℓ | 92.1 ± 32 | 97.5 ± 37.5 | 0.328 |
 C-reactive protein, mg/dℓ | 6.3 ± 8.2 | 1.5 ± 3.5 | < 0.001 |
In-hospital Stroke | 11 (32.4%) | 24 (7.8%) | < 0.001 |
Occlusion site | |||
 Middle cerebral artery | 24 (70.6%) | 172 (56.0%) | 0.143 |
  M1 | 18 (52.9%) | 118 (38.4%) | 0.139 |
  M2 | 6 (17.6%) | 54 (17.6%) | 0.993 |
 Anterior cerebral artery | 1 (2.9%) | 16 (5.2%) | 0.478 |
 Posterior cerebral artery/Basilar artery | 4 (11.8%) | 54 (17.6%) | 0.479 |
 Internal carotid artery | 5 (14.7%) | 63 (20.5%) | 0.504 |
 Common carotid artery | 0 (0%) | 2 (0.6%) | 0.998 |
Use of intravenous rtPA | 9 (26.5%) | 80 (26.1%) | 0.959 |